Dow Jones
33.761,05 +424,35 (+1,27%) Nasdaq
13.047,19 +267,29 (+2,09%) Nikkei 225
28.769,91 +222,93 (+0,78%) EUR/USD
1,0265 +0,0007 (+0,07%) BTC-EUR
23.769,17 -354,57 (-1,47%) CMC Crypto 200
582,86 +11,58 (+2,03%)
Cerevel Therapeutics Holdings, Inc. (CERE)
Dopo ore:
| Chiusura precedente | 35,63 |
| Aperto | 36,62 |
| Denaro | 32,22 x 1200 |
| Lettera | 35,80 x 1000 |
| Min-Max giorno | 33,63 - 36,62 |
| Intervallo di 52 settimane | 19,86 - 46,16 |
| Volume | |
| Media Volume | 719.356 |
| Capitalizzazione | 5,177B |
| Beta (5 anni mensile) | 2,09 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,71 |
| Prossima data utili | 08 nov 2022 - 14 nov 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 39,00 |
- GlobeNewswire
Cerevel Therapeutics Announces Pricing of $254 Million Public Offering of Common Stock and Concurrent $300 Million Private Offering of Convertible Senior Notes
CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 7,250,000 shares of its common stock at a public offering price of $35.00 per share, or approximately $253.8 million of shares of its common stock. In addition, Cerevel granted the u
- GlobeNewswire
Cerevel Therapeutics Announces Pricing of $300 Million Private Offering of Convertible Senior Notes and Concurrent $254 Million Public Offering of Common Stock
CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced private offering of $300.0 million aggregate principal amount of 2.50% convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under
- GlobeNewswire
Cerevel Therapeutics Announces Proposed Private Offering of Convertible Senior Notes
CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has commenced a private offering of $250.0 million aggregate principal amount of convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of
